95410-7SARS-CoV-2 (COVID-19) neutralizing antibody [Titer] in Serum by pVNTActive
Term Description
Quantitative titer results for SARS Coronavirus 2 (SARS-CoV-2) virus neutralizing antibodies in serum by pVNT (pseudovirus neutralization test). Neutralizing antibody testing is performed to determine whether the antibodies produced after SARS-CoV-2 infection or in response to a vaccination are able to neutralize the virus and prevent infection or re-infection. Different methods can be used to determine the presence of neutralizing antibodies, including VNT (virus neutralization test) and pVNT, which are represented in LOINC as the Method "Neutralization" and "pVNT", respectively. The pVNT method for SARS-CoV-2 neutralizing antibody testing uses recombinant pseudoviruses that incorporate the S protein from SARS-CoV-2, whereas VNT uses SARS-CoV-2 virus from a clinical isolate or recombinant SARS-CoV-2 expressing reporter proteins.
Source: Regenstrief LOINC
Part Description
LP417540-4 SARS coronavirus 2
The 2019 Novel Coronavirus (2019-nCoV) is a coronavirus first identified as the cause of a respiratory illness outbreak in Wuhan, China. Initially, the outbreak was linked to a large seafood and animal market and thought to only be spread by animal to person contact. Within a short time, a growing number of patients who had not been exposed to animal markets were diagnosed with the infection, indicating person-to-person transmission. As of January 2020, infections with 2019-nCoV have been reported internationally, including Thailand and the United States, in due to confirmed cases in travelers from Wuhan. Overall, clinical symptoms appear milder than SARS Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) infections as do the fatality rate and transmissibility. [PMID: 31953166] Reported illnesses have ranged from minor or no respiratory symptoms to severe acute respiratory illness and death.
The full genome of the 2019-nCoV was first posted by Chinese health authorities in GenBank, the NIH genetic sequence database, and in the Global Initiative on Sharing All Influenza Data (GISAI) portal. This facilitated detection of the virus globally with subsequent sequences being nearly identical, suggesting a single, recent emergence from a virus related to bat coronaviruses and the SARS coronavirus. Real time Reverse Transcription-Polymerase Chain Reaction (rRT-PCR) tests have been developed by the Centers for Disease Control and Prevention (CDC) and others for the diagnosis of 2019-nCoV. The existing 2019-nCoV primer and probe sets are designed for the universal detection of SARS-like coronaviruses and for specific detection of 2019-nCoV.[CDC: coronavirus/2019-ncov]
Source: LOINC
Fully-Specified Name
- Component
- SARS coronavirus 2 Ab.neut
- Property
- Titr
- Time
- Pt
- System
- Ser
- Scale
- Qn
- Method
- pVNT
Additional Names
- Short Name
- SARS-CoV-2 NAb Titr Ser pVNT
- Display Name
- SARS-CoV-2 (COVID-19) neut ab pVNT (S) [Titer]
- Consumer Name Alpha
- SARS-CoV-2 (COVID-19) neutralizing antibody, Blood
Ask At Order Entry
This panel contains a convenience grouping of terms for questions commonly asked when an order is placed in a public health laboratory.
LOINC | Name | R/O/C | Cardinality | Example UCUM Units |
---|---|---|---|---|
81959-9 | Public health laboratory ask at order entry panel | |||
Indent81744-5 | Submitter's laboratory test method [Type] in Specimen | |||
Indent81658-7 | Suspected organism [Identifier] in Specimen | |||
Indent86952-9 | Preliminary testing done Specimen | |||
Indent86953-7 | Preliminary testing result Specimen | |||
Indent86955-2 | Preliminary testing affected submission for further testing Specimen | |||
Indent95417-2 | Whether this is the patient's first test for condition of interest | |||
Indent95418-0 | Whether patient is employed in a healthcare setting | |||
Indent95419-8 | Whether the patient has symptoms related to condition of interest | |||
Indent11368-8 | Illness or injury onset date and time | C | ||
Indent77974-4 | Whether the patient was hospitalized for condition of interest | |||
Indent95420-6 | Whether the patient was admitted to intensive care unit (ICU) for condition of interest | |||
Indent95421-4 | Whether patient resides in a congregate care setting | |||
Indent82810-3 | Pregnancy status | C | ||
Indent30525-0 | Age | a |
Basic Attributes
- Class
- MICRO
- Type
- Laboratory
- First Released
- Version 2.68
- Last Updated
- Version 2.69
- Order vs. Observation
- Observation
Reference Information
Type | Source | Reference |
---|---|---|
Webcontent | Lab Tests Online®Copyright Copyright © 2001-2019 American Association for Clinical Chemistry | Coronavirus (COVID-19) Testing |
Member of these Groups
LG51018-6 | SARSCoV2 antibody detection |
Language Variants Get Info
- zh-CNChinese (China)
- SARS 冠状病毒 2 抗体.中和:
滴定度: 时间点: 血清: 定量型: 假病毒中和试验 - nl-NLDutch (Netherlands)
- SARS-CoV-2 As.neutraliserend:
titer: moment: serum: kwantitatief: pseudovirus-neutralisatietest - it-ITItalian (Italy)
- SARS coronavirus 2 Ab.Neut:
Titr: Pt: Siero: Qn: pVNT
Example Units
Unit | Source |
---|---|
{titer} | Example UCUM Units |
LOINC FHIR® API Example - CodeSystem Request Get Info
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=95410-7
LOINC Copyright
Copyright © 2020 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright